In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Two hundred isolates of Mycobacterium tuberculosis were evaluated for their susceptibility to a newly synthesised quinolone derivative, ER-2, compared with ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin. ER-2 and moxifloxacin showed the greatest activity [MIC for 90% of strains tested (MIC(90))=0.5 microg/mL], although levofloxacin and ciprofloxacin showed good activity with an MIC(90) of 1 microg/mL. More importantly, ER-2 showed excellent activity against M. tuberculosis H37Rv both in the lungs and spleen of mice, indicating the potential therapeutic value of ER-2 against M. tuberculosis.
Rao
Shilpakala Sainath
SS
Department of Genetics, Dr ALM PGIBMS, University of Madras, Taramani Campus, Chennai 600113, India.
Raghunathan
Raghavachari
R
Ekambaram
Ramesh
R
Raghunathan
Malathi
M
D000818:Animals; D000995:Antitubercular Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D015169:Colony Count, Microbial; D005260:Female; D006801:Humans; D008168:Lung / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D015363:Quinolones / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D013154:Spleen / Q000382:microbiology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology
D000995:Antitubercular Agents; D015363:Quinolones